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Abstract
Background: Human T-cell leukemia virus type 1 (HTLV-1) causes adult T-cell leukemia (ATL) and HTLV-1-
associated myelopathy/tropical spastic paraparesis (HAM/TSP) in a small percentage of infected individuals. ATL is
often associated with general immune suppression and an impaired HTLV-1-specific T-cell response, an important
host defense system. We previously found that a small fraction of asymptomatic HTLV-1-carriers (AC) already
showed impaired T-cell responses against the major target antigen, Tax. However, it is unclear whether the
impaired HTLV-1 Tax-specific T-cell response in these individuals is an HTLV-1-specific phenomenon, or merely
reflects general immune suppression. In this study, in order to characterize the impaired HTLV-1-specific T-cell
response, we investigated the function of Tax-specific CD8
+ T-cells in various clinical status of HTLV-1 infection.
Results: By using tetramers consisting of HLA-A*0201, -A*2402, or -A*1101, and corresponding Tax epitope
peptides, we detected Tax-specific CD8
+ T-cells in the peripheral blood from 87.0% of ACs (n = 20/23) and 100%
of HAM/TSP patients (n = 18/18) tested. We also detected Tax-specific CD8
+ T-cells in 38.1% of chronic type ATL
(cATL) patients (n = 8/21), although its frequencies in peripheral blood CD8
+ T cells were significantly lower than
those of ACs or HAM/TSP patients. Tax-specific CD8
+ T-cells detected in HAM/TSP patients proliferated well in
culture and produced IFN-g when stimulated with Tax peptides. However, such functions were severely impaired in
the Tax-specific CD8
+ T-cells detected in cATL patients. In ACs, the responses of Tax-specific CD8
+ T-cells were
retained in most cases. However, we found one AC sample whose Tax-specific CD8
+ T-cells hardly produced IFN-g,
and failed to proliferate and express activation (CD69) and degranulation (CD107a) markers in response to Tax
peptide. Importantly, the same AC sample contained cytomegalovirus (CMV) pp65-specific CD8
+ T-cells that
possessed functions upon CMV pp65 peptide stimulation. We further examined additional samples of two
smoldering type ATL patients and found that they also showed dysfunctions of Tax-specific but not CMV-specific
CD8
+ T-cells.
Conclusions: These findings indicated that Tax-specific CD8
+ T-cells were scarce and dysfunctional not only in ATL
patients but also in a limited AC population, and that the dysfunction was selective for HTLV-1-specifc CD8
+ T-cells
in early stages.
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Human T-cells leukemia virus type 1 (HTLV-1) is the
causative agent of a highly aggressive CD4
+ T-cell
malignancy, adult T-cell leukemia (ATL)[1,2]. As many
as 10 million individuals are thought to be infected
worldwide, in southern Japan, the Caribbean basin,
South America, Melanesia, and equatorial Africa[3].
Unlike human immunodeficiency virus (HIV), the
majority of HTLV-1-infected individuals are clinically
asymptomatic during their lifetime. However, approxi-
mately 5% develop ATL, and another 2-3% develop a
variety of chronic inflammatory diseases such as HTLV-
1-associated myelopathy/tropical spastic paraparesis
(HAM/TSP)[4-8].
HTLV-1-specific cytotoxic T-lymphocytes (CTLs) are
thought to play a pivotal role in containing the prolif-
eration of HTLV-1-infected T-cells[9,10]. Tax is known
to be the dominant target antigen for HTLV-1-specific
CTLs[10-13], and a high frequency of Tax-specific CTLs
can be detected in HAM/TSP patients and some asymp-
tomatic HTLV-1 carriers (ACs)[10-14]. However, ATL
patients show general immune suppression[15], reduced
frequency and dysfunction of Tax-specific CTLs[16,17].
Regulatory T cell (Treg)-like function of FoxP3
+ ATL
cells and diminished function of dendritic cells may be
involved in the immune suppression in ATL patients
[18,19], but the precise mechanism is not yet clarified.
We previously demonstrated that a fraction of ACs also
exhibit reduced T-cell responses against Tax protein
[20]. These observations suggest that the reduced
HTLV-1-specific T-cell response might be an underlying
risk of ATL development, but not the result of ATL.
However, it is unknown how the function of HTLV-1-
specific CD8
+ T-cells becomes impaired in a small per-
centage of ACs and whether its dysfunction is specific
for HTLV-1 antigen or due to general immune
suppression.
During chronic stage of infection with several viruses,
such as HIV and hepatitis C virus (HCV), virus-specific
CTLs gradually lose their cytotoxic activity, the ability
to proliferate and secrete a diverse profile of cytokines,
ultimately leading to exhaustion, anergy or even deletion
of these cells[21-26]. Programmed death-1 (PD-1), a
negative regulator in the CD28 superfamily, has recently
been shown to be highly expressed on virus-specific T-
cells during many chronic viral infections[27-29]. It has
also been reported that the interaction of PD-1 with
PD-ligand 1 (PD-L1) negatively regulates cytokine pro-
duction and proliferation of T-cells[30,31]. A previous
report indicates that PD-1 is up-regulated on the domi-
nant Tax-specific CTLs in ATL patients and ACs and
that immune regulation through the PD-1/PD-L1 path-
way may be involved in the dysfunction of HTLV-1-spe-
cific CTLs in ATL patients[32].
Studies on memory T-cell differentiation have shown
that phenotype, function, and homeostasis of memory
T-cells vary for different persistent virus infections[33].
Central memory T-cells (TCM;C D 4 5 R A
-CCR7
+)a r ee l i -
cited by non-persisting virus that provide transient anti-
gen stimulation, such as in Influenza virus infection. In
contrast, effector memory T-cells (TEM; CD45RA
-CCR7
-
) predominate when relatively high levels of antigen per-
sist, such as in HIV infection. Terminally differentiated
memory (TDiff; CD45RA
+CCR7
-) can be seen when anti-
gen persists at a low level, such as in cytomegalovirus
(CMV) infection. In HTLV-1 infection, it has been
reported that dominant Tax-specific CTLs in HAM/TSP
patients consist of TEM and TDiff compartments[34].
We previously identified some major epitopes recog-
nized by HTLV-1-specific CTLs in infected individuals
carrying HLA-A2, -A11, or -A24[12,35,36]. These
allowed us to monitor HTLV-1-specific CTLs and ana-
lyze their functions ex vivo, by using antigen/HLA tetra-
meric complexes. In this study, we demonstrate that
IFN-g production and proliferative capacity of tetramer-
binding Tax-specific CD8
+ T-cells were severely
impaired not only in ATL patients but also in a minor
population of asymptomatic HTLV-1 carriers (ACs).
Importantly, the T-cell dysfunction at the asymptomatic
stage was selective for HTLV-1 but not for CMV anti-
gen. In addition, severely impaired HTLV-1-specific but
not CMV-specific CD8
+ T-cells responses were also
observed in patients diagnosed as smoldering ATL, the
clinical condition of which is close to that of AC. The
dysfunction of HTLV-1-specific CD8
+ T-cells in an
early clinical stage implies HTLV-1-specific immune
suppressive mechanism might be an underlying risk for
ATL.
Results
Incidence and frequency of Tax-specific CD8
+ T-cells in
ACs, and HAM/TSP and cATL patients
In 23 ACs and 18 HAM/TSP and 21 cATL patients car-
rying HLA-A2, -A11 and/or -A24 alleles, we evaluated
the frequencies of Tax-specific CD8
+ T-cells by using
cognate Tax/HLA tetramers (Figure 1 and Table 1).
Tax-specific CD8
+ T-cells were detected in 87.0% of
ACs and all HAM/TSP patients tested. In contrast, only
38.1% of cATL patients have detectable frequencies of
Tax-specific CD8
+ T-cells (Table 1). Figure 1B shows
that the average frequency of Tax-specific CD8
+ T-cells
in the CD8
+ T-cells of cATL patients (n = 21, 0.90%
range: 0%-9.45%) was significantly lower than that in
ACs (n = 23, 2.37%, range: 0%-8.23%, P = 0.0023).
HAM/TSP patients had the highest average frequency of
Tax-specific CD8
+ T-cells among the three groups (n =
18, 8.88%, range: 1.86%-29.9%, P = 0.0001; vs. AC, P <
0.0001; vs. cATL patients), which is consistent with
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fic CD8
+ T-cells are detectable even in cATL patients,
although the frequency is very low.
Impaired cell proliferation and IFN-g production of Tax-
specific CD8
+ T-cells in cATL but not HAM/TSP patients
We next examined IFN-g production and cell prolifera-
tion of Tax-specific CD8
+ T-cells in HAM/TSP and
cATL patients (Figure 2A). Intracellular IFN-g staining
showed that Tax-specific CD8
+ T-cells in all HAM/TSP
patients tested produced IFN-g when stimulated with
Tax peptide (Figure 2A). Tax-specific CD8
+ T-cells in
those HAM/TSP patients proliferated regardless of sti-
mulation with Tax peptide (Figure 2B). In contrast to
HAM/TSP patients, IFN-g production from Tax-specific
CD8
+ T-cells in a cATL patient was hardly detectable
even when stimulated with Tax peptide (4.8%, Figure
2 A ) .I nt h es a m ed o n o r ,T a x - s p e c i f i cC D 8
+ T-cells
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Figure 1 Incidence and frequency of Tax-specific CD8
+ T-cells in ACs, and HAM/TSP and cATL patients. (A) Whole blood or PBMCs from
AC (top), and HAM/TSP (middle) and cATL (bottom) patients were stained with Tax/HLA tetramer. Number indicates the percentage of
tetramer
+ cells in CD8
+ T-cells. (B) The percentage of Tax-tetramer
+ CD8
+ T-cells in AC (n = 23), and HAM/TSP (n = 18) and cATL (n = 21)
patients. P value was determined by the Mann-Whitney U test. Horizontal bars indicate the average percentage of Tax-tetramer
+ CD8
+ T-cells for
the group.
Table 1 The number of blood samples with detectable Tax-specific CD8
+ T-cells in all samples tested in this study
Tax/HLA tetramers used in this study Disease Status
AC HAM/TSP cATL
HLA-A*0201/Tax11-19 12/14
1 7/7 2/11
HLA-A*1101/Tax88-96 4/4 4/4 3/5
HLA-A*2402/Tax301-309 13/15 13/13 5/16
No. of tetramer
+ samples/total no. of blood samples
2 20/23 (87.0%) 18/18 (100%) 8/21 (38.1%)
1 No. of samples with detectable Tax-specific CD8
+ T-cells/total no. of samples carrying each HLA allele. When the frequency of tetramer
+ cells was more than
0.04% of CD8
+ T-cells, the sample was regarded as detectable.
2 In case Tax-specific CD8
+ T-cells was detectable by either tetramer in a sample carrying two of three HLA-A alleles above, the sample was regarded as positive.
Takamori et al. Retrovirology 2011, 8:100
http://www.retrovirology.com/content/8/1/100
Page 3 of 15could be detected in fresh blood (1.32%) and after 6 hrs
incubation as shown in Figure 2A, but not after 6 day-
culture, suggesting that Tax-specific CD8
+ T-cells in
this cATL patient had no proliferative capacity (Figure
2B). We tested PBMC from four other cATL patients
who had detectable Tax-specific CD8
+ T-cells, but none
of them showed proliferation of Tax-specific CD8
+ T-
cells by either the CFSE-based proliferation assay or 13-
day culture (Additional file 1). Collectively, these results
indicate that Tax-specific CD8
+ T-cells from most cATL
patients are impaired in their capacities to proliferate
and produce IFN-g.
Diversity in the IFN-g production and cell proliferation of
Tax-specific CD8
+ T-cells in ACs
Our recent studies using the GST-Tax protein-based
assay demonstrated that the extent of Tax-specific T-
cell responses varied widely in ACs[20]. We then evalu-
ated proliferation and/or IFN-g production of tetramer-
binding Tax-specific CD8
+ T-cells in 14 ACs (Table 2).
Representative data on 4 of 14 ACs are shown in Fig-
ures 3A and 3B. In 3 ACs (#251, #313, and #360), Tax-
specific CD8
+ T-cells produced IFN-g and proliferated
in response to Tax peptide (Figures 3A and 3B). Simi-
larly to HAM/TSP samples, a large proportion of Tax-
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Figure 2 IFN-g production and proliferation of Tax-specific CD8
+ T-cells in HAM/TSP and cATL patients. (A) PBMCs from HAM/TSP and
cATL patients were stimulated with or without 10 μM Tax peptide for 6 hrs. The number indicates the percentage of IFN-g-producing cells in
tetramer
+ cells. (B) For CFSE-based T-cell proliferation, CFSE-labeled PBMCs from HAM/TSP and cATL patients were cultured in the presence or
absence of 100 nM Tax peptide for 6 days. The number indicates the percentage of dividing (CFSE
low) cells in tetramer
+ cells. The percentage of
tetramer
+ cells among CD8
+ T cells in fresh blood is indicated in parenthesis under the patient ID.
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+ T-cells in these ACs spontaneously prolif-
erated without stimulation with Tax peptide, probably
due to viral reactivation in HTLV-1-infected cells in
vitro[38,39]. IFN-g production was specifically detected
for peptide stimulation, and 35.8-55.7% of Tax-specific
CD8
+ T-cells produced a good amount of IFN-g (mean
fluorescence intensity, MFI: 63.7-195.3) upon stimula-
tion in the samples of #251, #313, and #360. In contrast,
Tax-specific CD8
+ T-cells in one AC (#287) did not
proliferate in response to Tax peptide and showed a
very weak IFN-g response with low amounts of IFN-g
(MFI: 37.5) in a low percentage (11.1%) of Tax-specific
CD8
+ T-cells (Figures 3A and 3B). In other ACs (#243
and #279), low frequency of IFN-g
+ Tax-specific CD8
+
T-cells was observed, but the levels of IFN-g production
(MFI: #243; 58.8, #279; 77.6) and the proliferative
responses were comparable to other ACs (Table 2).
Tax-specific CD8
+ T-cells in #236 failed to proliferate
but showed favorable IFN-g production (MFI: 80.1) in
31.1% of the cells.
Among AC samples tested, AC#287 carried higher
proviral load (81 copies in 1000 PBMCs) than any other
ACs (Table 2). Since Tax-specific CD8
+ T-cells in #287
had severely impaired IFN-g production and proliferative
potential, we examined the relationship of the function
of these T-cells with proviral loads. Both percentages of
IFN-g
+ and dividing Tax-specific CD8
+ T-cells among
CD8
+ T - c e l l sw e r el i k e l yt ob ei n v e r s e l yc o r r e l a t e dw i t h
proviral loads although they were not statistically signifi-
cant (Figure 3C and 3D). Because of the limited avail-
ability of the samples, we focused mainly on two ACs
(#287 and #313) in the studies hereafter.
Dysfunction of Tax-specific CD8
+ T-cells and inefficient
CD8
+ cell-mediated HTLV-1 control in AC #287
To examine whether Tax-specific CD8
+ T-cell responses
were influenced by activation of antigen-presenting cells
(APCs), PBMC from #313 (responder) and #287 (low
responder) were stimulated with Tax peptide in the pre-
sence or absence of LPS, a potent activator of APCs
such as dendritic cells (DCs) and monocytes/macro-
phages. In #313, the frequency of Tax-specific CD8
+ T-
cells increased from 1.11% to 6.47% or 4.07% at day 13,
after stimulation with or without Tax peptide, respec-
tively. The frequency of Tax-specific CD8
+ T-cells in
#313 further increased in the presence of Tax peptide
and LPS (15.81%). In contrast to #313, the frequency of
Tax-specific CD8
+ T-cells in #287 decreased from 1.17%
Table 2 Clinical information and summary for Tax-specific CD8
+ T cells in 14ACs
ID Age Sex WBC
(/μl)
CD4 (%)
1 CD8 (%)
1 HLA Tetramer (%)
2 Functions and phenotype of
Tax-specific CD8
+ T-cells
3
Ably (%)
7 PVL
8
IFN-g
+
(%)
4
CFSE
low
(%)
5
PD-1
+
(%)
6
#217 70s F 6800 ND
9 5.72 A24 1.94 27.7 78.9 78.7 0 14
#236 30 s F 6500 ND 11.9 A24 2.54 31.1 0 54.1 0 22
#238 60 s F 5700 ND 12.7 A11 1.29 36.4 100 0 0 2
#243 50 s F 4100 ND 24.6 A2/24 0.39/3.67 11.3 27.6 93.8 0 3
#245 40 s F 5000 ND 22.6 A2 0.73 62.5 75 ND 1 58
#251 60 s M 4800 ND 11.9 A2/11 0.70/8.23 35.8 84.4 36.7 0 2
#279 40 s M 6200 34.1 11.6 A2/24 4.70/0.18 12.9 30.8 70.2 1 48
#287 70 s M 4800 72.5 10.0 A2/24 1.17/0.23 11.1 0 55.6 2 81
#309 60 s F 4600 37.5 24.8 A11/24 6.88/4.26 51.7 76.2 85.3 1.5 29
#311 60 s F 3200 30.6 14.8 A2/24 1.02/1.94 51.3 ND ND 0 6
#312 50 s F 2700 27.3 36.4 A24 2.03 77.8 ND ND ND UN
10
#313 60 s M 7300 25.4 31.0 A24 1.11 55.7 60 90.6 ND 4
#315 50 s F 7500 26.5 7.9 A2/24 6.88/0 24.5 84.7 20 0.6 17
#360 50 s M 6200 37.7 29.9 A2 2.6 63.1 68.4 10.2 0 UN
1The number indicates percentage of CD4
+ or CD8
+ T cells in lymphocytes.
2The number indicates percentages of tetramer
+ cells in CD8
+ T-cells. Two numbers divided by a slash represent those detected by two different tetramers
corresponding to two HLA alleles shown in the HLA column.
3In case of a sample carrying two of three HLA-A alleles (A2, A11, or A24), Tax-specific CTLs predominantly detected by a tetramer were used. The number
represents percentage of indicated cells in the tetramer-binding CD8
+ T cells.
4Evaluated by intracellular IFN-g staining following 6 hours stimulation with corresponding Tax peptide.
5Evaluated by CFSE intensities in labeled PBMC after 6 days incubation with corresponding Tax peptide stimulation.
6The number represents percentage of indicated PD-1
+Tax-specific CD8
+ T cells without culture.
7Ably; abnormal lymphocytes
8PVL; proviral load. The number represents copy number per 1000 PBMCs.
9ND; not determined
10UN; undetectable
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Page 5 of 15Figure 3 IFN-g production and cell proliferation of Tax-specific CD8
+ T-cells in ACs. (A, B) IFN-g production (A) and cell proliferation (B) of
Tax-specific CD8
+ T-cells in PBMCs from 4 ACs were assessed as in Figure 2. The number given in parenthesis shows mean fluorescence
intensity (MFI) of IFN-g expression in the IFN-g
+ tetramer
+ cells. (C, D) Relation between the percentage of IFN-g
+ (C) or dividing (D) Tax-specific
CD8
+ T-cells and proviral loads (PVL) in ACs. Dots represent individual ACs. The Spearman rank correlation test was used to determine
correlations and P values.
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Page 6 of 15to 0.2% after stimulation with Tax peptide, and was not
recovered by LPS stimulation (Figure 4A). In addition,
HTLV-1-infected cells have been reported to express C-
C chemokine receptor type 4 (CCR4) and have FoxP3
+
Treg-like function[18,40]. However, the proliferative
ability of Tax-specific CD8
+ T-cells in #287 was not
restored even in the absence of CCR4
+ infected cells
(data not shown).
To further examine the function of Tax-specific CD8
+
T-cells in #313 and #287, we observed the expression of
CD69, an early activation marker transiently expressed
on T lymphocytes that precedes cytokine secretion after
antigenic stimulation, and CD107a, a marker of degra-
nulation associated with cytotoxic activity in an antigen-
specific manner[41]. CD69 was up-regulated on Tax-
specific CD8
+ T-cells in #313 when stimulated with Tax
peptide, but not in #287, which was in agreement with
their abilities to produce IFN-g (Figure 4B). In #313,
22.4% of Tax-specific CD8
+ T-cells mobilized CD107a
to the surface during a 6-hr culture with Tax peptide
stimulation, while CD107a surface expression was
detected on 4% of Tax-specific CD8
+ T-cells in the cul-
ture without stimulation (Figure 4C). However, no
CD107a mobilization was detected on the surface of
Tax-specific CD8
+ T-cells in #287 with or without Tax
peptide stimulation (Figure 4C). These results indicate
that HTLV-1-specific CD8
+ T-cells in AC #287 did not
properly activate upon antigen stimulation, and there-
fore failed to control HTLV-1-infected cells.
The Tax/HLA tetramers used in this study allow us to
evaluate the functions of CD8
+ T-cells only against an
immunodominant epitope, Tax. We therefore compared
HTLV-1 Gag p19 in the culture between whole and
CD8
+ cell-depleted PBMCs to examine the role of total
HTLV-1-specific CD8
+ T-cells including the dominant
Tax-specific CD8
+ T-cells, in suppression of HTLV-1
production from infected cells (Figure 4D). As expected,
depletion of CD8
+ cells from PBMCs in #313 led to sig-
nificantly higher HTLV-1 production compared to
whole PBMCs (P = 0.0115). In contrast, HTLV-1 p19
production increased only a little in the culture of CD8
+
cell-depleted PBMCs in #287 (P = 0.1563), indicating
that HTLV-1-specific CD8
+ T-cells other than the
dominant Tax-specific CD8
+ T-cells might have a
reduced ability to control the infected cells in this
donor. It is of note that HTLV-1-infected cells from
both two donors carried intact HTLV-1 proviral geno-
mic DNA because HTLV-1 p19 could be detected after
7 day-culture.
Phenotypic analysis of functional and dysfunctional Tax-
specific CD8
+ T-cells
We next characterized the differentiation status of
memory T-cells in Tax-specific CD8
+ T-cells. Human
CD8 T-cells may be classified as naïve T-cells (CD45RA
+CCR7
+CD27
+), TCM (CD45RA
-CCR7
+CD27
+), TEM
(CD45RA
-CCR7
-CD27
+), and TDiff (CD45RA
+CCR7
-
CD27
-) cells[42-44]. As shown in Figure 5A, almost all
Tax-specific CD8
+ T-cells in both #313 and #287 were
skewed to CD45RA
-CCR7
-CD27
+ TEM cells, and there
was no essential difference between two donors.
A previous report has shown that PD-1 was highly up-
regulated on Tax-specific CD8
+ T-cells in ATL patients
and ACs[32]. We therefore examined PD-1 expression
on Tax-specific CD8
+ T-cells in several AC samples,
including #287. The frequency of PD-1
+ Tax-specific
CD8
+ T-cells was very high in #309 (85.3%) and #313
(96%) (Figure 5B and Table 2) while those Tax-specific
CD8
+ T-cells retained the proliferative and the cytokine-
producing abilities (Figure 3A and Table 2). In #287, the
frequency of PD-1-expressing Tax-specific CD8
+ T-cells
(55.6%) was lower than #309 and #313, but higher than
that of PD-1
+ CMVpp65-specific CD8
+ T-cells in the
same donor (Figure 5B). The levels of PD-1 expression
showed a similar tendency to the frequency of PD-1
+ T-
cells. In addition, the blockade of PD-1/PD-ligand 1
(PD-L1) pathway did not restore the proliferative capa-
city of Tax-specific CD8
+ T-cells in #287 (data not
shown).
Conserved functions of CMV-specific CD8
+ T-cells in #287
We next examined whether the impairment of prolifera-
tive capacity and effector functions observed in #287
CD8
+ T-cells were specific for HTLV-1 antigens or the
result of general immune suppression. PBMC from #287
contained CMVpp65-specific CD8
+ T-cells (2.3% of
CD8
+ T-cells), as detected by tetramer staining. The fre-
quency of CMVpp65-specific CD8
+ T-cells increased
from 2.3% to 66.0% following in vitro CMVpp65 peptide
stimulation, but not without the peptide stimulation
(Figure 6A). Antigen-specific IFN-g and CD69 expres-
sion were clearly detected in CMVpp65-specific CD8
+
T-cells in #287 (Figures 6B and 6C). Furthermore,
CMVpp65-specific CD8
+ T-cells mobilized CD107a to
the surface in response to CMVpp65 peptide (Figure
6D). These results demonstrate that in #287, CMVpp65-
specific CD8
+ T-cells, but not Tax-specific CD8
+ T-
cells, have proliferative potential and effector functions,
such as cytotoxic activity and IFN-g release, suggesting
that the impaired CD8
+ T-cell function in #287 was spe-
cific for HTLV-1.
Dysfunction of Tax-specific but not CMVpp65-specific
CD8
+ T-cells also in sATL patients
Finally, we extended the study to see whether patients
with early stage ATL might exhibit similar dysfunction
selective for HTLV-1-specific CD8
+ T-cells. We found
two smoldering ATL (sATL) patients (#110 and #353)
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+ T-cells and inefficient CD8
+ cell-mediated HTLV-1 control in AC#287. (A) For antigen-specific
T-cell proliferation, PBMCs from #313 and #287 were cultured for 13 days with or without Tax peptide in the presence or absence of 0.1 μg/ml
LPS. The number indicates the percentage of tetramer
+ cells in CD8
+ T-cells. (B, C) PBMCs were stimulated with or without 10 μM Tax peptide
for 6 hrs. The expression of CD69 (B) and CD107a (C) in Tax-specific CD8
+ T-cells was analyzed by flow cytometry. (B) Bar indicates the
percentage of CD69
+ cells in Tax-specific CD8
+ T-cells. (C) The number represents the percentage of CD107a
+ cells in Tax-specific CD8
+ T-cells.
(D) Whole PBMCs and CD8-depleted fractions in ACs (#287 and #313) were cultured for 7 days and HTLV-1 p19 in the supernatants were
measured by HTLV-1 p19 ELISA. P value was determined by the unpaired t test.
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Page 8 of 15possessing 6.89% and 3.15% of tetramer-binding Tax-
specific CD8
+ T-cells, respectively. The sATL patient
#353 carried 5% of abnormal lymphocytes (ably) with a
normal range of lymphocyte number, whose status is
very close to the borderline with ACs. Patient #110 car-
ried 4% of abnormal lymphocytes with mild lymphocy-
tosis. Tax-specific CD8
+ T-cells of two sATL patients
(#110 and #353) did not proliferate in response to Tax
peptides as similarly observed in a cATL patient (#224)
(Figure 7A) and most other cATL patients (Figure 2A
and Additional file 1). In contrast, CMVpp65-specific
CD8
+ T-cells in both sATL patients vigorously prolifer-
ated when stimulated with CMVpp65 peptides.
CMVpp65-specific CD8
+ T-cells in a cATL (#224) also
proliferated, but to a lesser degree, which might reflect
general immune suppression in this patient (Figure 7).
Discussion
In this study, we detected Tax-specific CD8
+ T-cells in
87%, but not the rest of ACs tested, by using tetramers
containing Tax major epitope-peptides presented by
HLA-A*0201, A*1101, and A*2402. Tax-specific CD8
+
T-cells were also detected in 38% of cATL patients, but
at reduced frequencies and with severely impaired func-
tions. Further analysis of Tax-specific CD8
+ T-cells in
14 ACs indicated that they were functional in most of
ACs tested except one (#287), whose Tax-specific CD8
+
T-cells poorly responded to specific peptides. However,
CMVpp65-specific CD8
+ T-cells of this individual were
fully functional. Similar T-cell dysfunction selective for
HTLV-1, but not CMV, was also observed in sATL
patients, one of which (#353) had no clinical symptoms
but 5% abnormal lymphocytes. General immune sup-
pression might partly account for the scarcity and/or
the dysfunction of Tax-specific CD8
+ T-cells in ATL
patients, but not those in the AC or the sATL patients
as they were selective for HTLV-1. These findings sug-
gest that HTLV-1-specific immune suppression is
undergoing in a minor group of ACs and an early stage
of ATL.
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Page 9 of 15T h ep r e s e n c eo ft e t r a m e r - binding Tax-specific CD8
+
T-cells in cATL patients, although at low frequencies,
implies that they have encountered antigen during the
chronic phase of ATL disease, suggesting that Tax may
be expressed in vivo. This may be supported by a pre-
vious report showing that virus-specific CD8
+ T-cells
fails to acquire memory T-cell property of long-term
antigen-independent persistence during chronic lympho-
cytic choriomeningitis virus (LCMV) infection[45].
However, there is no direct evidence that infected cells
produce Tax in infected individuals. HTLV-1-specific T-
cell responses in cATL patients are largely different
from HAM/TSP patients. In HAM/TSP patients, Tax-
specific CD8
+ T-cells proliferated vigorously and a large
population of them produced IFN-g. In contrast, the
function of Tax-specific CD8
+ T-cells in cATL patients
was profoundly suppressed, similarly to tumor infiltrat-
ing lymphocytes (TIL)[46]. In cATL patients, Tax-speci-
fic CD8
+ T-cells that were detected before culture
decreased in number to undetectable or very low levels
after 6 days, regardless of peptide stimulation (data not
shown). This is not likely to be due to TCR down-regu-
lation, because TCRs on Tax-specific CD8
+ T-cells in
HAM/TSP patients are down-regulated on days 1 to 4
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Figure 6 Conserved functions of CMV-specific CD8
+ T-cells in AC#287. (A) For antigen-specific T-cell proliferation, PBMCs from #287 were
cultured for 13 days with or without 100 nM CMV peptide. The number indicates the percentage of CMV tetramer
+ cells in CD8
+ T-cells. (B-D)
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Page 10 of 15and reappeared by day 6 in vitro[34]. Moreover, we
could not observe any tetramer
+ CD8
+ T-cells even in
the 13-day culture (data not shown), suggesting these
cells might have died during the culture.
Severe dysfunction of Tax-specific CD8
+ T-cells was
observed not only in cATL patients, but also in an AC
#287. Fresh PBMCs of #287 contained 1.17% tetramer
+
cells in the CD8
+ T-cell fraction. However, none of
these tetramer-positive T-cells proliferated in culture,
with or without Tax peptide stimulation (Figure 3B).
Although a few populations of them (11.1%) produced a
small amount of IFN-g, they lacked degranulation activ-
ity for cytotoxicity or expression of CD69, an early acti-
vation marker, upon specific stimulation (Figures 3 and
4). Importantly, CMVpp65-specific CD8
+ T-cells in the
same donor were clearly activated, and exhibited these
characteristics upon stimulation with pp65 peptides
(Figure 6). These observations indicated that the
impaired Tax-specific CD8
+ T-cells function in #287
was not attributable to general immune suppression, but
to an HTLV-1-specific phenomenon. In addition, CD8-
depletion study indicated that not only the dominant
Tax-specific CD8
+ T-cell function but also other HTLV-
1-specific CD8
+ T cell responses might be reduced in
#287 (Figure 4D). Since CMV-specific CD8
+ T-cells
responded well to the specific peptides, antigen-present-
ing cells in culture were not likely to be responsible for
the selective suppression of Tax-specific CD8
+ T-cells.
In addition, it has been shown that HTLV-1-infected
cells generally express CCR4 and have Treg-like func-
tion[18,40]. However, depletion of CCR4
+ cells did not
restore the proliferative ability of Tax-specific CD8
+ T-
cells (data not shown), indicating that suppression of
the infected cells were not likely to be the major reason
for the impaired Tax-specific CD8
+ T-cell function in
our culture system. These observations suggest that in
#287, Tax-specific CD8
+ T-cells themselves might lose
their functions.
Many chronic viral infections affect the phenotype,
function, and maintenance of memory T-cells
[24,42,47,48]. TEM cells predominate in infections in
which relatively high levels of antigen persist and con-
tinuous antigen stimulation are required for mainte-
nance of TEM cells. As described in HAM/TSP patients
[34], Tax-specific CD8
+ T-cells in both ACs (#287 and
#313) were primarily enriched in TEM memory pool in
spite of the functionality of Tax-specific CD8
+ T-cells
(Figure 5A), which may support continuous or periodi-
cal expression of viral antigen in vivo during an asymp-
tomatic stage.
PD-1 is known to play a major role in regulating T-
cell exhaustion during chronic infection. In this study,
we could not obtain any data supporting the involve-
ment of PD-1 in the dysfunction of Tax-specific CD8
+
T-cells. However, we observed that Tax-specific CD8
+
T-cells in some ACs showed IFN-g production, but not
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Figure 7 Impaired proliferation of Tax-specific but not CMVpp65-specific CD8
+ T-cells in sATL patients. For antigen-specific T-cell
proliferation, PBMCs from sATL (#110; square, #353; triangle) and cATL (#224; circle) patients were cultured for 13 days with 100 nM Tax (A) or
CMV (B) peptide. Each dot indicates the percentage of tetramer
+ cells in CD8
+ T-cells at day 0 and day 13 after culture. Clinical information on
ATL patients used here is as follows; sATL#110: age; 40 s, gender; F, WBC#; 11,000/μL {lymphocyte (lym); 39%, abnormal lymphocytes (ably); 4%},
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function of Tax-specific CD8
+ T-cells is similar to the
features of T-cell exhaustion. Whether Tax-specific CD8
+ T-cells are exhausted in HTLV-1 infection, and
whether other molecules associated with T-cell exhaus-
tion are involved in the impairment of Tax-specific CD8
+ T-cell responses are necessary to be clarified because
some inhibitory molecules such as T-cell immunoglobu-
lin and mucin domain-containing protein-3 (TIM-3),
lymphocyte activated gene-3 (LAG-3), and transcription
factors including BLIMP-1 are also found to be asso-
ciated with T-cell exhaustion [49].
The incidence of Tax-specific CD8
+ T-cell detection
was high (87.0%) in ACs. Given the fact that the inci-
dence of Tax-specific CD8
+ T-cells in HAM/TSP
patients was 100%, a small fraction of ACs lacking
detectable tetramer-binding cells might lack Tax-specific
T-cell responses. Our previous study investigating GST-
Tax protein-based T-cell responses supports this notion
[20]. In the present study, even in ACs possessing Tax-
specific CD8
+ T-cells, at least one individual exhibited
T-cell dysfunction selectively for HTLV-1. The inci-
dence of tetramer-positive cells was reduced in ATL
patients (38.1%), and the function of these cells was
impaired in all the ATL patients even with detectable
tetramer-binding Tax-specific CD8
+ T-cells. Our find-
ings suggest that HTLV-1-specific T-cell responses are
selectively impaired in a small percentage of HTLV-1-
infected individuals in the asymptomatic stages, and the
proportion of individuals wi t hs u c hc h a r a c t e r i s t i c s
increase as the stages proceed towards ATL. Strategies
to reactivate HTLV-1-specific T-cells at early stages
might contribute to a reduction in the immunological
risk of ATL.
Conclusions
Tax-specific CD8
+ T-cells were scarce and dysfunctional
in a limited AC population and ATL patients, and the
dysfunction of CD8
+ T-cells was selective for HTLV-1
in early stages. These results implied the presence of
some HTLV-1-specific T-cell suppressive mechanisms
even in asymptomatic stages, which are not a result of
general immune suppression in ATL but could be
underlying conditions toward disease progression.
Methods
Samples
Blood samples from 64 HTLV-1-seropositive individuals
were used in this study: 23 asymptomatic carriers (ACs),
18 HAM/TSP patients, 2 smoldering type ATL (sATL)
patients, and 21 chronic type ATL (cATL) patients. All
blood samples were obtained following written informed
consent, and this study was reviewed and approved by
the Institutional Review Board of the Tokyo Medical
and Dental University.
Peptides
Peptides used in this study were HLA-A2-restricted CTL
epitopes (Tax11-19, LLFGYPVYV)[12] (Hokudo Co.,
Hokkaido, Japan) and (CMV495-503, NLVPMVATV)[50]
(Sigma Aldrich St. Louis, MO), HLA-A11-restricted CTL
epitope (Tax88-96, KVLTPPITH)[36] (Hokudo Co) and
HLA-A24-restricted CTLs epitopes (Tax301-309,
SFHSLHLF)[35] (Hokudo Co) and (CMV341-349,
QYDPVAALF)[51] (Sigma Aldrich).
Cell Surface staining
To select samples carrying HLA-A2, -A11, or -A24,
whole blood was screened with antibodies for HLA-A2,
-A11, and -A24 subtypes (One Lambda, Inc., Los
Angeles, CA). FITC-conjugated goat anti-mouse Ig (G
+M) (Beckman Coulter Inc., Webster, TX) was used as
a secondary antibody. For cell surface staining, whole
blood samples were stained with the following fluoro-
chrome-conjugated mouse anti-human mAbs; CD3-
FITC, CD8-PE/Cy5, CD8-PerCP/Cy5.5 (RPA-T8, BioLe-
gend), CD27-FITC (O323, BioLegend) CD45RA-FITC
(HI 100, BD Biosciences), CD45RA-APC (HI 100, Bio-
Legend), CD69-FITC (FN 50, BioLegend), PD-1-FITC
(EH12.2H7, BioLegend), CCR7 (TG8/CCR7, Biolegend).
Tetramer staining
PE-conjugated HLA-A*0201/Tax11-19, HLA-A*1101/
Tax88-96, HLA-A*2402/Tax301-309, HLA-A*0201/
CMVpp65, HLA-A*2402/CMVpp65 tetramers were pur-
chased from MBL (Nagoya, Japan). Whole blood sam-
ples or peripheral blood mononuclear cells (PBMCs)
were stained with PE-conjugated Tax/HLA tetramer in
conjunction with FITC-conjugated anti-CD3 (UCHT1,
BioLegend San Diego, CA), and PE-Cy5-conjugated
anti-CD8 monoclonal antibodies (mAbs) (HIT8a, BD
Biosciences San Jose, CA). Whole blood samples were
lysed and fixed in BD FACS lysing solution (BD Bios-
ciences) before washing the cells. Samples were analyzed
on a FACSCalibur (Becton Dickinson, San Jose, CA)
and data analyses were performed using CellQuest soft-
ware (Becton Dickinson).
Tetramer-based IFN-g flow cytometry
Tetramer-based intracellular IFN-g flow cytometry was
performed as described previously[17], with slight modi-
fications. In brief, PBMCs (2.0 × 10
5 cells) were incu-
bated with HLA tetramer-PE and anti-CD8-PE/Cy5,
washed, and stimulated with 10 μM antigenic peptide
for 6 hrs at 37°C in the presence of brefeldin A (BFA,
10 μg/ml; Sigma Aldrich). The cells were stained with a
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IFN-g-FITC (4S.B3, BD Biosciences).
T-cell proliferation
PBMCs (2.0-5.0 × 10
5 cells/well) labeled with carboxy-
fluorescein succinimidyl ester (CFSE; Sigma Aldrich)
were cultured for 6 days with or without 100 nM anti-
genic peptide and then stained with Tax/HLA tetramer-
PE and anti-CD8-PE/Cy5. In some experiments, PBMCs
(2.0 × 10
5 cells) were cultured for 13 days with 100 nM
antigenic peptide and 10 U/ml recombinant human IL-2
(IL-2; Shionogi, Osaka, Japan) in the presence or
absence of 0.1 μg/ml Lipopolysaccharide (LPS; Sigma
Aldrich). The cells were then stained with HLA tetra-
mer-PE, anti-CD8-PE/Cy5 and anti-CD3-FITC, and ana-
lyzed by flow cytometry.
Quantification of HTLV-1 proviral load
The HTLV-1 proviral load was measured using LightCy-
cler DNA Master SYBR Green 1 (Roche, Mannheim, Ger-
many) with a LightCycler (Roche). Genomic DNA was
extracted from PBMCs (2 × 10
6 cells) using DNeasy Blood
& Tissue kits (QIAGEN, Courtaboeuf, France). The pri-
m e rs e t su s e di nt h i ss t u d yw e r ea sf o l l o w s :p X 2( 5 ’-
CGGATACCCAGTCTACGTGTTTGGAGACTGT-3’)
and pX3 (5’-GAGCCGATAACGCGTCCATCGATGG
GGTCC-3’) for HTLV-1 pX, and B-globin (5’-ACA-
CAACTGTGTTCACTAGC-3’)a n da B - g l o b i n( 5 ’-
CAACTTCATCCACGTTCACC-3’)f o rb-globin. The
proviral load was calculated as: [(copy number of pX)/
(copy number of b-globin/2)] × 1000. HTLV-1 proviral
loads in some of the PBMC samples were measured by the
Group of Joint Study on Predisponsing Factors of ATL
Development (JSPFAD, Japan) as described previously
[20].
CD107a mobilization assay
PBMCs were stained with Tax/HLA tetramers-PE and
anti-CD8-PE/Cy5, washed, and stimulated with 10 μM
antigenic peptide for 6 hrs at 37°C in the presence of
mouse anti-human CD107a-PerCP/Cy5.5 (H4A3, Biole-
gend) or mouse IgG1-PerCP/Cy5.5 (MOPC-21, Biole-
gend). BFA (10 μg/ml) was added 1 hr after incubation
was started. The cells were then collected and stained
with an HLA tetramer.
Depletion of CD8
+ cells and Detection of HTLV-1 p19
CD8
+ cells were depleted from PBMCs by negative selec-
tion using 10-fold numbers of Dynabeads M-450 CD8
(Invitrogen, Carlsbad, CA), according to the manufac-
turer’s instructions. The PBMCs were adjust to 1 × 10
6
cells/ml before depletion, and the resulting CD8
+ cell-
depleted fractions were resuspended in medium with the
same initial volume, irrespective of the remaining cell
number. PBMCs (1 × 10
6 cells/ml) and CD8
+ cell-
depleted PBMCs were cultured for 7 days. HTLV-1 p19
in the supernatants of those PBMCs were measured by
HTLV p19 antigen ELISA (RETRO tek, Buffalo, NY).
Statistics
The Mann-Whitney U-test, the unpaired t test, and the
Spearman rank correlation test were performed for sta-
tistical significance by using the Graphpad Prism soft-
ware (Graphpad Software). In all cases, two-tailed P
values less than 0.05 were considered significant.
Additional material
Additional file 1: Tax-specific CD8
+ T-cells in cATL patients could
not proliferate against Tax-peptide stimulation. (A) CFSE-labeled
PBMCs were cultured with or without 100 nM Tax-peptide for 6 days.
The number indicates the percentage of tetramer
+ cells in CD8
+ T cells
(Day 0) or the percentage of dividing (CFSE
low) cells in Tax-specific CD8
+
T-cells (Day 6). In a cATL sample #54, CFSE-labeled PBMCs were cultured
in the presence of mouse IgG for other experiment. (B) PBMCs (#224)
and CCR4-depleted PBMCs (#280) were cultured for 13 days in the
presence of 100 nM Tax-peptide. The number indicates the percentage
of tetramer
+ cells in CD8
+ T-cells.
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